Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 19/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 19/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 19/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 19/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13949116 | 1.00 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4163890 | 0.83 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8270542 | 0.82 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4821406 | 0.82 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4818588 | 0.82 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4166372 | 0.80 | CTNNB1 (0.44) | — | |
| SCHEMBL4824626 | 0.80 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4824632 | 0.80 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4816849 | 0.77 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4816854 | 0.77 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042875-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION | 2009-02-12 | — | — | US | disclosed |
| US-20090042875-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE CORPORATION | 2009-02-12 | — | — | US | disclosed |
| US-7468446-B2 | Substituted heterocyclic compounds and uses thereof | CELGENE CORPORATION (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468446-B2 | Substituted heterocyclic compounds and uses thereof | CELGENE CORPORATION (US) | 2008-12-23 | — | — | US | disclosed |
| CN-101052630-A | Substituted heterocyclic compounds and uses thereof | CELGENE CORP (US) | 2007-10-10 | — | — | CN | disclosed |
| US-20060052596-A1 | Substituted heterocyclic compounds and uses thereof | CELGENE CORPORATION | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052596-A1 | Substituted heterocyclic compounds and uses thereof | NQO1, LTC4S, VHL | PDE4A 1046/4885PDE4B 798/4885PDE4C 767/4885 |
| US-20090042875-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND USES THEREOF | NQO1, LTC4S, VHL | PDE4A 1046/4885PDE4B 798/4885PDE4C 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.